We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

213 hedge funds and large institutions have $4.13B invested in Ionis Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 73 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

14% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 73

6% more capital invested

Capital invested by funds: $3.91B → $4.13B (+$219M)

4% more funds holding

Funds holding: 204 → 213 (+9)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

33% less call options, than puts

Call options by funds: $45.9M | Put options by funds: $68.7M

Holders
213
Holders Change
+9
Holders Change %
+4.41%
% of All Funds
6.18%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
34
Increased
83
Reduced
73
Closed
24
Calls
$45.9M
Puts
$68.7M
Net Calls
-$22.8M
Net Calls Change
-$4.77M

Top Buyers

1
SAM
Sectoral Asset Management
Quebec, Canada
+$27.8M
2
ACM
Apex Capital Management
Ohio
+$27M
3
WRF
Waddell & Reed Financial
Kansas
+$18M
4
RIM
Rainier Investment Management
Washington
+$18M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$17.4M

Top Sellers

1
GIM
Granahan Investment Management
Massachusetts
-$31.6M
2
BB
BB Biotech
Switzerland
-$28M
3
PC
PointState Capital
New York
-$27.2M
4
MG
Meditor Group
Bermuda
-$18.4M
5
BA
BlackRock Advisors
Delaware
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
76
Citadel Advisors
Florida
$3.79M +$3.39M +95,233 New
BIM
77
Bogle Investment Management
Massachusetts
$3.79M -$4.46M -125,303 -57%
Zurich Cantonal Bank
78
Zurich Cantonal Bank
Switzerland
$3.79M +$713K +20,000 +27%
Barclays
79
Barclays
United Kingdom
$3.7M +$1.38M +38,869 +69%
MLICM
80
Metropolitan Life Insurance Company (MetLife)
New York
$3.57M +$54.9K +1,542 +2%
PAMU
81
Pictet Asset Management (UK)
United Kingdom
$3.35M +$2.26M +63,400 +306%
AIG
82
American International Group
New York
$3.12M +$62.7K +1,761 +2%
PA
83
Profund Advisors
Maryland
$3.02M +$548K +15,378 +25%
SIA
84
Sit Investment Associates
Minnesota
$3.02M -$67.7K -1,900 -2%
MNBTD
85
Moody National Bank Trust Division
Texas
$2.96M – – –
Citigroup
86
Citigroup
New York
$2.92M +$1.02M +28,616 +64%
TD Asset Management
87
TD Asset Management
Ontario, Canada
$2.82M +$132K +3,700 +6%
VOYA Investment Management
88
VOYA Investment Management
Georgia
$2.65M +$62.5K +1,754 +3%
DekaBank Deutsche Girozentrale
89
DekaBank Deutsche Girozentrale
Germany
$2.62M +$92.6K +2,600 +4%
ProShare Advisors
90
ProShare Advisors
Maryland
$2.51M -$1.83M -51,471 -45%
AQR Capital Management
91
AQR Capital Management
Connecticut
$2.5M +$97.9K +2,747 +5%
Royal Bank of Canada
92
Royal Bank of Canada
Ontario, Canada
$2.43M +$1.11M +31,143 +104%
SONJCPFA
93
State of New Jersey Common Pension Fund A
New Jersey
$2.39M – – –
LCG
94
Lisanti Capital Growth
New York
$2.27M +$1.4M +39,390 +222%
Susquehanna International Group
95
Susquehanna International Group
Pennsylvania
$2.26M -$6.99M -196,139 -78%
SFP
96
Santa Fe Partners
New Mexico
$2.25M +$2.01M +56,486 New
MOACM
97
Mutual of America Capital Management
New York
$2.17M +$338K +9,496 +21%
Connor, Clark & Lunn Investment Management (CC&L)
98
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.16M -$103K -2,900 -5%
U
99
UBS
Switzerland
$2.02M -$179K -5,031 -9%
ACM
100
Avalon Capital Management
California
$1.99M -$33.6K -944 -2%
2 3
4
5 6

IONS Hedge Fund Activity: Q4 2013 in Review

213 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2013, worth a combined $4.13B — up 5.6% from $3.91B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new IONS positions and 24 closed out — a net gain of 10 holders — while 83 added to existing stakes and 73 trimmed.

The largest buyer was Sectoral Asset Management, adding an estimated $27.8M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $31.6M sold.

  • 213 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2013, up from 204 in Q3 2013.
  • Funds reported $4.13B of Ionis Pharmaceuticals stock for Q4 2013, up 5.6% quarter-over-quarter.
  • 34 funds opened new Ionis Pharmaceuticals positions in Q4 2013 and 24 closed out, a net change of +10 holders.
  • The largest Ionis Pharmaceuticals buyer in Q4 2013 was Sectoral Asset Management, an estimated $27.8M added.
  • The largest Ionis Pharmaceuticals seller in Q4 2013 was Granahan Investment Management, an estimated $31.6M sold.

Based on aggregated 13F filings for Q4 2013.